AR125397A1 - Modified ferroportin inhibitors - Google Patents
Modified ferroportin inhibitorsInfo
- Publication number
- AR125397A1 AR125397A1 ARP220101031A ARP220101031A AR125397A1 AR 125397 A1 AR125397 A1 AR 125397A1 AR P220101031 A ARP220101031 A AR P220101031A AR P220101031 A ARP220101031 A AR P220101031A AR 125397 A1 AR125397 A1 AR 125397A1
- Authority
- AR
- Argentina
- Prior art keywords
- membered
- branched
- fused
- linear
- ring
- Prior art date
Links
- 108091006976 SLC40A1 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000001188 haloalkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 229910052742 iron Inorganic materials 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 abstract 1
- 206010065973 Iron Overload Diseases 0.000 abstract 1
- 208000016286 Iron metabolism disease Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000005015 aryl alkynyl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000018511 hepcidin Human genes 0.000 abstract 1
- 229940066919 hepcidin Drugs 0.000 abstract 1
- 108060003558 hepcidin Proteins 0.000 abstract 1
- 125000005312 heteroarylalkynyl group Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a compuestos novedosos de fórmula general (1), que se caracterizan por que al menos uno de los grupos A y B contiene al menos 3 anillos, a composiciones farmacéuticas que los comprenden y al uso de los mismos como medicamentos, en particular para el uso como inhibidores de la ferroportina, más particularmente para el uso en la profilaxis y/o el tratamiento de enfermedades causadas por un déficit de hepcidina o trastornos del metabolismo del hierro que conducen a un aumento de los niveles de hierro o a un aumento de la absorción de hierro, y/o a una sobrecarga de hierro. Reivindicación 1: Compuestos de acuerdo con la fórmula (1) en donde l es un número entero de 1 o 2; m y n son independientemente un número entero de 1, 2 o 3; X¹ es N, S u O; X² es N, S, O ó CR⁴; X³ es C o N; con la condición de que uno de X¹ y X² sea N y si X³ es N, entonces X² es CR⁴; y en donde R⁴ representa H, halógeno, alquilo C₁-C₃ lineal o ramificado, haloalquilo C₁-C₃ lineal o ramificado, o A representa uno de los siguientes grupos (a-1), (a-2), (a-3), (a-4) y (a-5) del grupo de fórmulas (2), en donde * indica la posición de unión; R¹ y R² representan independientemente H, halógeno, alquilo C₁-C₃ lineal o ramificado, haloalquilo C₁-C₃ lineal o ramificado, alcoxi C₁-C₃ lineal o ramificado; en las fórmulas (a-2), (a-3) y (a-4) uno de C1, C2 y C3 está presente y en la fórmula (a-5) tanto C4 como C5 están presentes, y C1, C2, C3, C4 y C5 representan independientemente un anillo arilo de 6 miembros fusionado, un anillo heteroarilo de 5 o 6 miembros fusionado, un anillo cicloalquilo de 5 o 6 miembros fusionado, un anillo heterociclilo de 5 o 6 miembros fusionado; y en donde los grupos (a-2), (a-3), (a-4) y (a-5) llevan 0, 1, 2 o 3 sustituyentes, que se seleccionan independientemente entre halógeno, alquilo C₁-C₃ lineal o ramificado, haloalquilo C₁-C₃ lineal o ramificado, alcoxi C₁-C₃ lineal o ramificado; B representa uno de los siguientes grupos (b-1), (b-2) y (b-3) del grupo de fórmulas (3), en donde * indica la posición de unión; R³ representa H, arilo de 6 miembros no sustituido o sustituido, heteroarilo de 5 o 6 miembros no sustituido o sustituido, heteroarilo bicíclico no sustituido o sustituido, cicloalquilo de 5 o 6 miembros, heterociclilo de 5 o 6 miembros, heterociclilalquilo de 5 o 6 miembros, arilalquilo de 6 miembros, arilalquinilo de 6 miembros no sustituido o sustituido heteroarilalquinilo de 5 o 6 miembros no sustituido o sustituido, o un grupo fenilo, que forma un anillo bicíclico fusionado con un grupo cicloalquilo o heterociclilo de 5 o 6 miembros; Z¹ representa N o C, con la condición de que no más de un Z¹ represente N; en las fórmulas (b-2) y (b-3) uno de D1, D2 y D3 está presente y representa un anillo arilo de 6 miembros fusionado, un anillo heteroarilo de 5 o 6 miembros fusionado, un anillo cicloalquilo de 5 o 6 miembros fusionado, un anillo heterociclilo de 5 o 6 miembros fusionado; y en donde los grupos (b-2) y (b-3) llevan 0, 1, 2 o 3 sustituyentes, que se seleccionan independientemente entre halógeno, alquilo C₁-C₃ lineal o ramificado, haloalquilo C₁-C₃ lineal o ramificado, alcoxi C₁-C₃ lineal o ramificado; Z² y Z³ representan N o C, con la condición de que Z² pueda representar N cuando D2 está presente y Z³ pueda representar N cuando D3 está presente; y en donde los compuestos de fórmula (1) se caracterizan por que al menos uno de los grupos A y B contiene al menos 3 anillos; y sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21169916 | 2021-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125397A1 true AR125397A1 (es) | 2023-07-12 |
Family
ID=75639816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101031A AR125397A1 (es) | 2021-04-22 | 2022-04-21 | Modified ferroportin inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240239780A1 (es) |
| EP (1) | EP4326717A1 (es) |
| JP (1) | JP2024514363A (es) |
| KR (1) | KR20230175217A (es) |
| CN (1) | CN117321050A (es) |
| AR (1) | AR125397A1 (es) |
| AU (1) | AU2022260526A1 (es) |
| CA (1) | CA3215987A1 (es) |
| MX (1) | MX2023012442A (es) |
| TW (1) | TW202304896A (es) |
| WO (1) | WO2022223689A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024083980A1 (en) | 2022-10-21 | 2024-04-25 | Vifor (International) Ag | Bicyclic ferroportin inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011029832A1 (de) | 2009-09-09 | 2011-03-17 | Vifor (International) Ag | Neue thiazol- und oxazol-hepcidin-antagonisten |
| WO2017068090A1 (en) | 2015-10-23 | 2017-04-27 | Vifor (International) Ag | Novel ferroportin inhibitors |
| JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| US20230212159A1 (en) | 2020-03-24 | 2023-07-06 | Vifor (International) Ag | Process for the Production of Ferroportin Inhibitors |
-
2022
- 2022-04-12 TW TW111113855A patent/TW202304896A/zh unknown
- 2022-04-21 MX MX2023012442A patent/MX2023012442A/es unknown
- 2022-04-21 WO PCT/EP2022/060546 patent/WO2022223689A1/en active Application Filing
- 2022-04-21 CA CA3215987A patent/CA3215987A1/en active Pending
- 2022-04-21 US US18/556,128 patent/US20240239780A1/en active Pending
- 2022-04-21 KR KR1020237037405A patent/KR20230175217A/ko unknown
- 2022-04-21 AR ARP220101031A patent/AR125397A1/es unknown
- 2022-04-21 AU AU2022260526A patent/AU2022260526A1/en active Pending
- 2022-04-21 JP JP2023564662A patent/JP2024514363A/ja active Pending
- 2022-04-21 CN CN202280030137.4A patent/CN117321050A/zh active Pending
- 2022-04-21 EP EP22724448.0A patent/EP4326717A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117321050A (zh) | 2023-12-29 |
| TW202304896A (zh) | 2023-02-01 |
| AU2022260526A1 (en) | 2023-10-19 |
| JP2024514363A (ja) | 2024-04-01 |
| WO2022223689A1 (en) | 2022-10-27 |
| AU2022260526A9 (en) | 2023-10-26 |
| KR20230175217A (ko) | 2023-12-29 |
| MX2023012442A (es) | 2023-11-07 |
| EP4326717A1 (en) | 2024-02-28 |
| CA3215987A1 (en) | 2022-10-27 |
| US20240239780A1 (en) | 2024-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200008A1 (es) | Isoquinolinas como inhibidores de hpk1 | |
| AR082886A1 (es) | Compuestos y composiciones farmaceuticas que los contienen | |
| AR090488A1 (es) | Derivados de n-ciclobutilbenzamida, un proceso para su obtencion, intermediarios para su sintesis, composiciones pesticidas y farmaceuticas que los comprenden y metodos para controlar daños debidos a una plaga y/u hongos | |
| AR088293A1 (es) | Inhibidores de proteina cinasa | |
| AR117102A1 (es) | Inhibidores de arg1 y/o arg2 | |
| AR088352A1 (es) | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina | |
| PE20181496A1 (es) | Inhibidores de ferroportina novedosos | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR052903A1 (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno. | |
| AR052866A1 (es) | Fenil-metanonas monociclicas sustituidas | |
| MX2015013348A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos. | |
| AR060173A1 (es) | Derivados de piridina y de pirimidina como antagonistas del mglur2, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos del snc. | |
| AR098337A1 (es) | Triazolopirazina | |
| ECSP10010473A (es) | Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización | |
| AR117398A1 (es) | Inhibidores de la señalización mediada por tirosina cinasa 2 | |
| AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| AR105975A1 (es) | Sulfonamidas tricílicas limitadas heterocíclicas como agentes contra el cáncer | |
| AR125397A1 (es) | Modified ferroportin inhibitors | |
| AR104512A1 (es) | Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap) | |
| HN2011003482A (es) | Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb) | |
| AR121744A1 (es) | MODULADORES DE a 1-ANTITRIPSINA | |
| AR119348A1 (es) | MODULADORES DEL RECEPTOR a RELACIONADO CON ESTRÓGENO (ERRa) | |
| EA200501530A1 (ru) | Новые соединения бензотиадиазина, способ их получения и фармацевтические композиции, которые их содержат | |
| CU20210006A7 (es) | Derivados de fenil-n-quinolina y proceso para su preparación | |
| AR105460A1 (es) | Derivados sustituidos de 2-pirimidina furano / tienocicloalquilamino y su uso para el control del crecimiento de plantas no deseables |